Bayer (OTCPK:BAYR.Y) Update / briefing February 17, 2026 12:30 PM ET Company ParticipantsAnja Ettel - News reporterBill Anderson - CEOBill Dodero - Head of Litigation and North America LegalCharles Pitman-King - VPDietrich Knauth - Media RepresentativeJost Reinhard - Head of Investor RelationsSonja Wind - News ReporterWolfgang Nickl - CFOConference Call ParticipantsAlec Ebeling - Equity Research AnalystBert Günther - Equity Research AnalystLaurent Favre - Equity Research AnalystRajesh Kumar - Equity Researc ...

Financial Data and Key Metrics Changes - Total revenue increased by 19% to $3.7 billion in 2025, driven by strong execution across the royalty portfolio and commercialized medicines [25][26] - Operating profit expanded to $1.26 billion, reflecting strong execution and increasing operating leverage as the business scales [26][30] - Sales of proprietary medicines totaled $632 million, up 54% year-over-year, accounting for approximately 28% of total revenue growth [16][25] Business Line Data and Key Metrics Changes - Epkinly achieved $468 million in sales for 2025, representing a 67% year-over-year increase, driven by its dual indication in diffuse large B-cell lymphoma and follicular lymphoma [17][19] - Tivdak generated $164 million in sales, a 26% year-over-year increase, maintaining market leadership in recurrent or metastatic cervical cancer [20][21] Market Data and Key Metrics Changes - Epkinly closed 2025 with regulatory approvals in over 65 countries, nearly all featuring the dual indication [17] - The U.S. market saw increased uptake for Epkinly, particularly in community settings, with a majority of health systems ordering from multiple sites [18] Company Strategy and Development Direction - The company aims to accelerate the development of its late-stage pipeline and maximize the potential of its commercialized medicines, with a focus on sustainable growth into the 2030s [5][6] - The acquisition of Merus is expected to enhance the late-stage portfolio with petosemtamab, providing multiple value-creating catalysts in 2026 and beyond [8][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to execute on key data readouts in 2026 and subsequent high-impact launches in 2027, emphasizing a disciplined approach to capital allocation [31] - The company anticipates continued momentum in Epkinly and its royalty portfolio, with a revenue growth guidance of 14% for 2026 [27][30] Other Important Information - The company has five combined breakthrough therapy designations for its late-stage programs, which have multi-billion dollar potential [9] - The company is committed to deleveraging, targeting gross leverage below 3x by the end of 2027 [30] Q&A Session Summary Question: Next steps for Epkinly following EPCORE DLBCL-1 study results? - Management confirmed that the study showed positive progression-free survival but missed overall survival, and discussions with regulatory agencies are ongoing regarding the next steps [34][36] Question: Update on outpatient data for Epkinly? - Management indicated that the outpatient study is crucial for modifying the label and facilitating administration in the community [43][46] Question: Expectations for Rina-S pivotal phase two readout? - Management stated that the study is designed to support accelerated approval based on overall response rate and duration of response [51][54] Question: Expectations for EPCORE DLBCL 4 trial? - Management expressed optimism that the trial will lead to registration in second-line and third-line settings, differentiating it from other studies [58][60] Question: Thoughts on pembro approval in PROC and implications for Rina-S? - Management acknowledged the approval as a good option for patients but believes Rina-S can be more transformative for a broader population [62][64] Question: Confirmation on interim results for Epkinly frontline DLBCL trial? - Management reiterated that the readout for the study is expected to happen in 2026 [55][68]

Genmab (NasdaqGS:GMAB) Q4 2025 Earnings call February 17, 2026 12:00 PM ET Company ParticipantsAnthony Pagano - CFOBenjamin Jackson - VP of Equity ResearchBrad Bailey - CCOJames Gordon - Director and Head of European Pharma and Biotech & Life Sciences Equity ResearchJan van de Winkel - CEOJudith Klimovsky - Chief Development OfficerMatthew Phipps - Group Head–BiotechnologyTahamtan Ahmadi - CMOVictor Floc'h - Equity Research of PharmaceuticalsXian Deng - Executive Director and Pharma and Biotech Equity Resea ...

Financial Data and Key Metrics Changes - Total revenue increased by 19% to $3.7 billion in 2025, driven by strong execution across the royalty portfolio and commercialized medicines [24][25] - Operating profit expanded to $1.26 billion, reflecting strong execution and increasing operating leverage as the business scales [25][27] - Sales of proprietary medicines totaled $632 million, up 54% year over year, accounting for approximately 28% of total revenue growth [14][24] Business Line Data and Key Metrics Changes - Epkinly achieved $468 million in sales for the year, representing a 67% year-over-year increase, driven by its dual indication in diffuse large B-cell lymphoma and follicular lymphoma [15][24] - Tivdak generated $164 million in sales, representing a 26% year-over-year increase, maintaining market leadership in recurrent or metastatic cervical cancer [19][20] Market Data and Key Metrics Changes - Epkinly closed 2025 with regulatory approvals in more than 65 countries, nearly all featuring the dual indication [15] - The U.S. market saw increased uptake for Epkinly, particularly following its approval in second-line follicular lymphoma [17][18] - Tivdak's launch in Germany showed strong uptake, with positive physician feedback [20] Company Strategy and Development Direction - The company aims to accelerate the development of its late-stage pipeline and maximize the potential of its commercialized medicines [5][24] - The acquisition of Merus is expected to enhance the late-stage portfolio with petosemtamab, contributing to sustainable growth [6][25] - The focus for 2026 includes advancing proprietary portfolio impact, expanding market footprint, and preparing for multiple product launches [22][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to execute on key data readouts in 2026 and subsequent high-impact launches in 2027 [29] - The company anticipates continued revenue growth driven by Epkinly and its royalty portfolio, with a guidance of 14% total revenue growth for 2026 [26][28] - Management highlighted the importance of maintaining substantial profitability while investing in growth opportunities [27][28] Other Important Information - The company has five combined breakthrough therapy designations for its late-stage programs, indicating multi-billion dollar potential [7] - The anticipated data readouts in 2026 are expected to set the stage for multiple important product launches and line extensions in 2027 [8][10] Q&A Session Summary Question: Next steps for Epkinly following EPCORE DLBCL-1 study results - Management confirmed that the study showed positive progression-free survival but missed overall survival, with ongoing discussions with regulatory agencies about the data [31][33] Question: Update on outpatient data for Epkinly - Management indicated that the outpatient study is crucial for modifying the label and facilitating administration in the community [40][42] Question: Expectations for Rina-S pivotal phase two readout - Management stated that the study is designed to support accelerated approval based on overall response rate and duration of response [47][49] Question: Expectations for EPCORE DLBCL-4 trial outcomes - Management expressed optimism that the trial will lead to registration in second-line and third-line settings, differentiating it from other studies [53][55] Question: Thoughts on pembro approval in PROC and implications for Rina-S - Management acknowledged the approval as a good option for patients but believes Rina-S can be more transformative for a broader population [57][59] Question: Clarification on phase 3 for petosemtamab - Management confirmed that the phase 3 studies have dual endpoints of overall response rate and overall survival, which are standard in areas of unmet medical need [75]

Summary of Wheaton Precious Metals Conference Call Company Overview - **Company**: Wheaton Precious Metals (NYSE: WPM) - **Event**: Silver Stream Transaction conference call regarding Antamina mine - **Date**: February 17, 2026 Key Points Industry and Company Context - Wheaton Precious Metals is positioned as the largest precious metal streaming company globally, with a focus on silver production [3][4] - The company has acquired an additional silver stream on the Antamina mine in Peru, partnering with BHP [3][4] Acquisition Details - **Transaction Value**: $4.3 billion for 33.75% of the silver produced at Antamina, marking the largest precious metal stream ever executed [3][4][8] - **Payment Structure**: Upfront payment of $4.3 billion and ongoing payments equal to 20% of the spot silver price [8][19] - **Production Forecast**: Attributable silver production is expected to average approximately 6 million ounces per year for the first five years and 5.4 million ounces per year for the first ten years [9] Production Guidance and Growth - Updated production guidance indicates a 50% growth by 2030, targeting 1.2 million gold equivalent ounces annually [4][17] - Antamina is projected to contribute approximately 18% of Wheaton's total production by 2030, solidifying its position as the second-largest asset in the portfolio [9][11] Asset Quality and Longevity - Antamina is recognized as a long-life, low-cost operation, contributing to immediate production and cash flow [5][11] - The mine has a proven track record of extending its life through resource conversion and exploration, with a current mine life extended to 2036 [12][63] - The asset is expected to operate for decades, with significant exploration potential and ongoing investments in infrastructure [12][36] Financial Position and Strategy - Wheaton plans to fund the acquisition through a combination of existing liquidity, free cash flows, and a new $1.5 billion term loan [19] - The company anticipates generating over $10 billion in operating cash flow through 2028 at current spot prices, with a return to a net cash position expected within a year [19][98] - The transaction represents only 6.5% of Wheaton's total market capitalization, indicating strong strategic fit and accretion potential [19] Community and Sustainability Commitment - Wheaton emphasizes its commitment to supporting local communities and sustainability practices, particularly in Peru [10] Market Outlook - The silver market is expected to remain in a supply deficit for the next five years, with increasing investment demand [58] - Wheaton's management expresses confidence in the long-term fundamentals of silver, despite recent price fluctuations [58] Risk Management - The acquisition reduces concentration risk, as Antamina will represent under 18% of Wheaton's total assets, while Salobo will be under 25% in the coming years [39][40] - The company maintains a strong credit position with 70% of its exposure to investment-grade mining partners, significantly decreasing credit risk [11] Future Opportunities - Wheaton is exploring additional opportunities for growth, particularly in the copper space, which is expected to require significant capital investment [82] Additional Insights - The transaction with BHP is seen as a validation of the streaming model, highlighting its attractiveness as a source of capital for major mining companies [84] - The company is actively engaging with other large miners for potential future streaming agreements [82]

Summary of Wheaton Precious Metals Conference Call on Antamina Silver Stream Transaction Company and Industry - **Company**: Wheaton Precious Metals (NYSE: WPM) - **Industry**: Precious Metals Streaming and Mining Key Points and Arguments Acquisition Details - Wheaton Precious Metals announced the acquisition of an additional silver stream on the Antamina mine in Peru, partnering with BHP, for an upfront payment of **$4.3 billion** [3][4] - This transaction represents the largest precious metal stream ever executed, granting Wheaton **33.75%** of the silver produced until **100 million ounces** are delivered, after which it will receive **22.5%** for the mine's life [7][8] Production Guidance and Growth - Wheaton's updated production guidance indicates a **50% growth** by **2030**, targeting approximately **1.2 million gold equivalent ounces** annually [4][16] - Antamina is expected to contribute about **18%** of Wheaton's total production by **2030**, solidifying its position as the second-largest asset in Wheaton's portfolio [8][10] Market Context and Demand - The demand for silver is rising due to its critical industrial uses and safe haven qualities in the current economic environment, while sourcing quality silver production is becoming increasingly challenging [3][4] - The silver price has seen significant fluctuations, with the current market conditions influencing Wheaton's conservative pricing strategy for the acquisition [57][58] Financial Position and Funding - The upfront payment will be funded through a combination of existing liquidity, expected free cash flows, and a new **$1.5 billion** term loan, alongside a **$900 million** draw on Wheaton's existing credit facility [17][18] - Wheaton anticipates generating over **$10 billion** in operating cash flow through **2028** at current spot prices, allowing for a return to a net cash position within a year [18] Asset Quality and Longevity - Antamina is recognized as a long-life, low-cost operation, with a mine life extended to **2036** following recent approvals for expansion [11][12] - The mine has consistently outperformed expectations, delivering **17%** more silver than anticipated since Wheaton's first stream agreement in **2015** [14][54] Community and Sustainability Commitment - Wheaton emphasizes its commitment to supporting local communities, particularly through educational initiatives in the Ancash region of Peru, reflecting its values in responsible development [9] Exploration Potential - Antamina has a large exploration program, with ongoing drilling expected to upgrade inferred resources and define potential at depth, indicating a strong potential for extending the mine life beyond **2036** [11][33] Risk Management and Diversification - The acquisition is seen as a strategic move to diversify Wheaton's asset concentration, reducing reliance on its largest asset, Salobo [38] - Wheaton is actively exploring additional opportunities to further diversify its portfolio, including potential acquisitions from other joint venture partners [39][41] Conclusion - The transaction with BHP marks a significant step for Wheaton, enhancing its growth profile and reinforcing its position as a leader in the precious metal streaming sector [20][21]

Ralliant (NYSE: RAL) 2026 Conference Summary Company Overview - Ralliant is a global precision technologies company focused on designing, manufacturing, selling, and servicing products for critical, mission-critical outdoor environments [doc id='7'][doc id='10']. - The company has recently completed its first two quarters as an independent, publicly traded entity and is optimistic about its growth trajectory [doc id='2']. Key Financial Highlights - Ralliant's guidance for Q1 2026 indicates a growth rate of 5%-8%, compared to a historical growth rate of 3% [doc id='3']. - The midpoint of the 2026 growth guidance is set at 4%, with adjusted EBITDA margins projected at 18%-20%, which is below the long-term target of low to mid-20s [doc id='4'][doc id='12']. - A share buyback program has been executed for $39 million, with an authorization for up to $200 million [doc id='4']. - The company reported an adjusted EPS of $2.22-$2.42 for 2026 [doc id='13']. Growth Strategy and Market Position - Ralliant's growth strategy includes a focus on innovation and customer-centric solutions, particularly in defense, utilities, and power electronics [doc id='10']. - The company has identified strong growth vectors in defense and utilities, with expectations of outperforming market growth rates in these sectors [doc id='18']. - The industrials segment has shown signs of recovery, with a positive Q4 performance, while the Test and Measurement (T&M) segment is expected to return to growth in 2026 [doc id='20']. Operational Insights - Ralliant has implemented a cost savings program aimed at achieving $9-$11 million in savings due to operational inefficiencies post-spin [doc id='13']. - The company is focused on dynamic resource allocation, shifting resources from G&A to R&D to drive growth [doc id='17']. - Ralliant's RBS (Ralliant Business System) playbook is central to its operational efficiency and productivity initiatives [doc id='16']. New Product Innovations - Ralliant has significantly increased its new product innovations, with expectations of doubling historical averages in the T&M business [doc id='37']. - The company has introduced several new platforms, including the modular MP5000 platform, which is expected to accelerate innovation [doc id='38']. - In the defense sector, Ralliant reported over 24 new customer-funded products, indicating a strong pipeline for future growth [doc id='39']. Market Dynamics and Challenges - The company acknowledges that its operational expenses (OpEx) have been higher than anticipated, impacting profitability [doc id='14']. - Ralliant is navigating macroeconomic volatility and cyclical recovery in its end markets, with a focus on stabilizing growth [doc id='32']. - The T&M segment is characterized by short cycle business dynamics, which provides visibility into near-term performance [doc id='54']. Capital Allocation and Future Outlook - Ralliant plans to prioritize organic reinvestment into the business, with a CapEx increase from 2% to 2%-3% to support growth initiatives [doc id='67']. - The company is committed to returning cash to shareholders through dividends and share buybacks while exploring tuck-in M&A opportunities [doc id='68']. - Ralliant is optimistic about leveraging AI for operational efficiencies and enhancing customer value [doc id='69']. Conclusion - Ralliant is positioned for growth with a clear strategy focused on innovation, customer engagement, and operational efficiency. The company is navigating challenges while maintaining a disciplined approach to capital allocation and market expansion.

Financial Data and Key Metrics Changes - The consolidated adjusted EBITDA for 2025 was $219.2 million, down $53.6 million from the prior year, primarily due to changes in contract and spot coke sales, lower economics on the Granite City contract extension, and lower handling volumes [5][10] - The fourth quarter net loss attributable to SunCoke was $1 per share, down $1.28 compared to Q4 2024, mainly driven by one-time items totaling $0.85 per share net of tax [8][9] - Full year net loss attributable to SunCoke was $0.52 per share, down $1.64 from 2024, influenced by one-time items including non-cash asset impairment charges [8][9] Business Line Data and Key Metrics Changes - The domestic coke business delivered full-year adjusted EBITDA of $170 million, down $64.7 million from the prior year, impacted by contract and spot coke sales mix and the Algoma breach [10] - The industrial services segment, including Phoenix Global, delivered full-year adjusted EBITDA of $62.3 million, an increase of $11.9 million year-over-year, primarily due to the addition of Phoenix Global [11] - Corporate and other expenses increased by $800,000 year-over-year to $13.1 million, reflecting results from legacy coal mining and Brazil coke-making businesses [11] Market Data and Key Metrics Changes - The domestic coke segment is expected to deliver adjusted EBITDA between $162 million and $168 million in 2026, with sales of approximately 3.4 million tons [16][18] - Industrial services adjusted EBITDA is projected to be between $90 million and $100 million in 2026, reflecting expectations for improved market conditions [19][20] Company Strategy and Development Direction - The company plans to utilize free cash flow to support capital allocation priorities, including paying down revolver balance and maintaining dividends [22][23] - The integration of Phoenix Global is progressing well, with expectations for growth potential in this business [7][23] - The company aims to maintain strong safety and environmental performance, which is central to delivering high-quality coke and industrial services [22] Management's Comments on Operating Environment and Future Outlook - Management anticipates a meaningful recovery in 2026, supported by an optimized coke fleet and extended coke-making contracts [15] - The company expects consolidated adjusted EBITDA to be between $230 million and $250 million in 2026, with a focus on deleveraging and maintaining a gross leverage target below 3x [15][21] - Management highlighted the impact of ongoing litigation with Algoma, expecting to recover losses from the breach of contract [28][30] Other Important Information - The company returned approximately $41 million to shareholders via dividends in 2025 and plans to continue this in 2026 [7] - Capital expenditures for 2025 were $66.8 million, slightly below the revised guidance of $70 million [13] Q&A Session Summary Question: Status of litigation with Algoma - Management confirmed they are pursuing arbitration against Algoma for breach of contract and expect to prevail [28][30] Question: EBITDA contribution from Phoenix Global - Management affirmed the anticipated annual EBITDA contribution from Phoenix Global is still expected to be around $60 million, with synergies of $5 million-$10 million [32] Question: Haverhill One closure and potential reopening - Management stated that Haverhill One could be restarted but would require significant capital investment and about 12-18 months [42] Question: Impact of Middletown turbine failure - Management indicated that the turbine failure will have a $10 million impact in the first quarter, with no earnings from power production until it is operational again [46][48] Question: Expected improvement in tons handled in the industrial segment - Management noted that guidance includes a full year of the new KRT contract and modest recovery across both KRT and CMT [52]

Financial Data and Key Metrics Changes - In 2025, the company achieved a record Adjusted EBITDA of $497 million, representing a 7% increase year-over-year [4] - The fourth quarter saw a 47% increase in Adjusted EBITDA and a 340 basis point improvement in Adjusted EBITDA margin [18] - Gross profit for the fourth quarter increased by 27%, achieving a record gross margin of nearly 19% [18] Business Line Data and Key Metrics Changes - Aggregates volumes increased by 17% in the fourth quarter, with pricing up by 8% [18] - Ready Mix volumes rose by 20% in the fourth quarter, with gross margin lifting by 230 basis points [20] - Contracting services revenue grew by 15%, with the Mountain region experiencing nearly 20% growth [22] Market Data and Key Metrics Changes - The company entered 2026 with a record backlog of $1 billion, a 38% increase from the previous year [11] - Approximately 46% of IIJA funding remains to be disbursed across the company's 14 states, indicating strong public budgets [11] - The company anticipates continued growth in states with higher infrastructure spending, particularly in California, Alaska, and Hawaii [12] Company Strategy and Development Direction - The company focuses on four growth components: market positioning, vertical integration, self-help initiatives, and a strong corporate culture [6] - The acquisition program ramped up in 2025, with five deals completed and expectations for continued activity in 2026 [4][7] - The company aims to enhance margins through continuous improvement and operational excellence initiatives [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position for growth, citing favorable market conditions and strong infrastructure funding [5][11] - The company expects consolidated revenue for 2026 to be between $3.3 billion and $3.5 billion, with Adjusted EBITDA between $520 million and $560 million [26] - Management highlighted the importance of cost control and dynamic pricing strategies to drive future profitability [38] Other Important Information - The company invested $789 million in growth initiatives in 2025, including acquisitions and organic projects [23] - Maintenance capital expenditures were in line with expectations at 6% of revenue [24] - The company ended the year with nearly $75 million in unrestricted cash and a net leverage position of 2.2 times [25] Q&A Session Summary Question: Opportunities to build on backlog in the West region - Management acknowledged a geographic shift in backlog but expressed confidence in funding and opportunities in California, Hawaii, and Alaska [32][33] Question: Potential levers to outperform aggregate pricing expectations - Management noted strong pricing performance in 2025 and highlighted the implementation of dynamic pricing strategies as a key lever for future pricing [34][38] Question: Margin outlook for 2026 - Management indicated expectations for modest margin improvement, driven by dynamic pricing and operational efficiencies [42][44] Question: Return to year-over-year growth in Oregon - Management expects Oregon's performance in 2026 to be in line with 2025 results, contingent on public funding clarity [46][48] Question: Contribution of acquisitions to 2026 growth - Management stated that the contributions from acquisitions would offset seasonal losses and emphasized organic growth in guidance [88][90] Question: Data centers and backlog conversion - Management reported significant opportunities in data centers, primarily in material supply, with a strong pipeline of pending work [78][80]

Financial Data and Key Metrics Changes - The company reported a record full-year Adjusted EBITDA of $613.8 million and Distributable Cash Flow (DCF) of $385.7 million, both representing significant achievements for the company [3][11] - In Q4 2025, net income was $27.8 million, operating income was $76.6 million, and net cash provided by operating activities was $139.5 million [10] - The average pricing per horsepower reached an all-time high of $21.69, marking a 1% increase sequentially and a 4% increase year-over-year [10] Business Line Data and Key Metrics Changes - The total fleet horsepower at the end of Q4 was approximately 3.9 million, with an average utilization rate of 94.5% [10][11] - Expansion capital expenditures for Q4 were $40 million, while maintenance capital expenditures were $7.8 million [11] - The company plans to budget approximately 105,000 new horsepower for 2026, representing a 2% increase in active horsepower [6] Market Data and Key Metrics Changes - Natural gas production increased approximately 9% year-over-year, while oil production flattened in the latter half of the year due to lower oil prices [4][5] - The average natural gas price was $3.52 per MMBTU, a 56% increase from the prior year [5] - Lead times for new equipment have increased to over two years, presenting both opportunities and challenges for the company [5] Company Strategy and Development Direction - The acquisition of J-W Power is expected to enhance the company's presence across major oil and gas basins in the U.S. and improve service quality [3][4] - The company aims to achieve annual run-rate synergies of approximately $10 million to $20 million by the end of 2027 through operational optimizations [7][8] - The focus will be on increasing customer retention and extending average contract durations while integrating the J-W assets [8] Management's Comments on Operating Environment and Future Outlook - The management expressed confidence in the long-term prospects of the Permian Basin despite a slowdown in development pace due to lower oil prices [4] - The company is optimistic about the fundamentals of the compression industry, which continues to maintain strong margins and a disciplined approach to new capital [5] - Management highlighted the importance of managing debt levels and improving distribution coverage, with a target leverage ratio of 3.75x [14][25] Other Important Information - The company has refinanced its ABL and senior notes, significantly reducing borrowing costs and improving strategic flexibility [3][14] - The integration of a new ERP system is planned for Q1 2026, which will facilitate the integration of J-W assets [7] Q&A Session Summary Question: Growth CapEx guidance breakdown - The growth capital budget of $250 million includes approximately $205 million tied to the typical compression business, with $150 million for new units [19][21] Question: Balance sheet improvement and distribution coverage - The company aims for a normalized distribution coverage of 1.55x, with expectations to grow beyond 1.6x in the coming year [25] Question: Timing of new capacity delivery - Most of the new horsepower is expected to come online in the back half of the year, primarily from July onward [28] Question: Impact of lead times on pricing - Lead times for new packages are currently over 120 weeks, which complicates planning but will not affect 2026 growth [37] Question: Evaluation of distributed power space - The company is continuously evaluating opportunities in the distributed power space but has not yet found suitable candidates [33]